Loading...
XNAS
AIMDW
Market cap492kUSD
Jul 11, Last price  
0.12USD
1D
16.24%
1Q
44.05%
Name

Ainos Inc

Chart & Performance

D1W1MN
P/E
P/S
23.74
EPS
Div Yield, %
Shrs. gr., 5y
77.99%
Rev. gr., 5y
12.06%
Revenues
21k
-83.02%
154,565133,94270,069109,83652,2545,15058,395530001,9750250,92877,72411,73116,563594,5633,519,627122,11220,729
Net income
-15m
L+7.93%
-669,011-2,777,661-2,506,073-1,923,067-2,971,207506,312-1,313,773-650,847-622,602-622,602-521,874-669,982-617,375-1,338,639-1,582,183-1,460,811-3,904,803-14,037,168-13,770,549-14,863,161
CFO
-6m
L+23.72%
-655,391-1,461,207-1,412,052-948,811-903,114-584,538-309,705-489,442-664,248-554,981-366,414-520,808-542,703-1,009,198-909,476-499,551-1,249,977-3,021,183-4,694,668-5,808,267
Earnings
Aug 04, 2025

Profile

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.
IPO date
Aug 08, 1996
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
21
-83.02%
122
-96.53%
3,520
491.97%
Cost of revenue
8,467
13,329
8,960
Unusual Expense (Income)
NOPBT
(8,446)
(13,206)
(5,441)
NOPBT Margin
Operating Taxes
800
800
30
Tax Rate
NOPAT
(8,447)
(13,207)
(5,471)
Net income
(14,863)
7.93%
(13,771)
-1.90%
(14,037)
259.48%
Dividends
Dividend yield
Proceeds from repurchase of equity
(301)
46,000
BB yield
Debt
Debt current
3,000
42
1,261
Long-term debt
9,000
5,922
16
Deferred revenue
Other long-term liabilities
349
136
Net debt
8,107
4,078
(577)
Cash flow
Cash from operating activities
(5,808)
(4,695)
(3,021)
CAPEX
(21)
(93)
(634)
Cash from investing activities
(125)
(102)
(630)
Cash from financing activities
8,026
4,924
3,831
FCF
(8,130)
(12,708)
(30,446)
Balance
Cash
3,893
1,886
1,853
Long term investments
Excess cash
3,892
1,880
1,677
Stockholders' equity
(53,005)
(38,108)
(24,117)
Invested Capital
80,870
68,655
60,014
ROIC
ROCE
EV
Common stock shares outstanding
9,504
4,098
2,727
Price
Market cap
EV
EBITDA
(3,644)
(8,335)
(607)
EV/EBITDA
Interest
616
144
54
Interest/NOPBT